FDA-cleared profile

qER-Quant

Qure.ai Technologies · CT/CTA · FDA-cleared (510(k))

Automatic labeling, visualization, and quantification of segmentable brain structures from non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; single-timepoint volumes and longitudinal comparisons are provided when scans use the same scanner and protocol for the same person.

Clinical role
Automated labeling, segmentation/contouring, visualization, volume or shift quantification, and same-protocol longitudinal comparison through the user's radiology workflow.
Images and patients
CT/CTA · Brain; intracranial hyperdensities, lateral ventricles, and midline shift
Key limitation
The indication is limited to non-contrast head CT and the three named target structures; longitudinal comparison requires the same scanner, acquisition protocol, and individual. The packet does not establish an intended-user label or a diagnostic-outcome claim.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyCT/CTA · Brain; intracranial hyperdensities, lateral ventricles, and midline shift
  • Workflow roleAutomated labeling, segmentation/contouring, visualization, volume or shift quantification, and same-protocol longitudinal comparison through the user's radiology workflow.
  • Required inputNon-contrast head CT in DICOM format; the plain axial series is processed.
  • Output and human actionPDF and DICOM outputs with volumes, preview images, labeled overlays, and longitudinal graphics showing changes in absolute volume and size when comparable scans are available.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatic labeling, visualization, and quantification of segmentable brain structures from non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; single-timepoint volumes and longitudinal comparisons are provided when scans use the same scanner and protocol for the same person.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Automated labeling, segmentation/contouring, visualization, volume or shift quantification, and same-protocol longitudinal comparison through the user's radiology workflow.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Non-contrast head CT in DICOM format; the plain axial series is processed.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
PDF and DICOM outputs with volumes, preview images, labeled overlays, and longitudinal graphics showing changes in absolute volume and size when comparable scans are available.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Limitations
The indication is limited to non-contrast head CT and the three named target structures; longitudinal comparison requires the same scanner, acquisition protocol, and individual. The packet does not establish an intended-user label or a diagnostic-outcome claim.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
Standalone testing used expert-manually labeled head CTs and reported target-specific absolute errors and Dice scores: intracranial hyperdensity, 183 scans, mean absolute error 6.56 (7.33) mL and Dice 0.75 (95% CI 0.72-0.78); midline shift, 188 scans, mean absolute error 1.37 (1.23) mm with no Dice reported; left lateral ventricle, 210 scans, mean absolute error 2.09 (1.88) mL and Dice 0.79 (95% CI 0.78-0.81); right lateral ventricle, 210 scans, mean absolute error 2.18 (1.72) mL and Dice 0.75 (95% CI 0.73-0.77). Absolute error and Dice are measurement and segmentation endpoints, not sensitivity or specificity.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone testing used expert-manually labeled head CTs and reported target-specific absolute errors and Dice scores: intracranial hyperdensity, 183 scans, mean absolute error 6.56 (7.33) mL and Dice 0.75 (95% CI 0.72-0.78); midline shift, 188 scans, mean absolute error 1.37 (1.23) mm with no Dice reported; left lateral ventricle, 210 scans, mean absolute error 2.09 (1.88) mL and Dice 0.79 (95% CI 0.78-0.81); right lateral ventricle, 210 scans, mean absolute error 2.18 (1.72) mL and Dice 0.75 (95% CI 0.73-0.77). Absolute error and Dice are measurement and segmentation endpoints, not sensitivity or specificity.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

qER-Quant regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested version1.0
  • Samplen=375
  • IndependenceIndependence not established

K211222

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K211222. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Non-contrast head CT in DICOM format; the plain axial series is processed.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K211222: qER-Quant

  2. Routing

    Source context, not route validation: CT scans are received from the user's PACS or another radiology software system/database and results are returned to the same destination or a user-specified radiology system; DICOM is used for input and output.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K211222: qER-Quant

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: PDF and DICOM outputs with volumes, preview images, labeled overlays, and longitudinal graphics showing changes in absolute volume and size when comparable scans are available.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K211222: qER-Quant

  5. Viewer/worklist/report

    Unresolved route: PDF and DICOM outputs with volumes, preview images, labeled overlays, and longitudinal graphics showing changes in absolute volume and size when comparable scans are available.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K211222: qER-Quant

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
CT scans are received from the user's PACS or another radiology software system/database and results are returned to the same destination or a user-specified radiology system; DICOM is used for input and output.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Qure.ai's documentation FAQ says data is sent over HTTPS (TLS 1.2 or higher), stored encrypted at rest with AES-256-GCM, backed up with restore tests twice a year, and that Qure maintains an ISO 27001 certification with periodic surveillance audits. It also says hospitals anonymize PHI before sending data. The certificate itself was not read and no date or scope is given.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Monitoring
Qure.ai's vulnerability disclosure programme states that it covers all Qure.ai commercial products, including cloud-hosted products and Qure.ai-operated infrastructure, and commits to handling every report promptly and transparently with an acknowledgement and tracking reference within 2 business days.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Qure.ai generally and does not scope these commitments to any specific product release; exact-release scope is not established. The programme is an intake and response-handling commitment; it makes no uptime, drift or continuous-monitoring claims.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for qER-Quant; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K211222
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact FDA indication and input description specify non-contrast head CT; CTA is not established by the packet. Controlled directory display reconciled from exact FDA wording: Non-contrast head CT. -> CT/CTA.

Anatomy
Brain; intracranial hyperdensities, lateral ventricles, and midline shift
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-07-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
24Fields reviewed
11Source classes checked
1Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 1 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not name the intended users of the subject device. Confirm intended operators and readers with the vendor.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K211222 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

9 sources - 2 history items

Source ledger

  1. FDA K211222: qER-Quant

    U.S. Food and Drug Administration - Published 2021-07-30 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. qER-Quant model card (K211222)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K211222

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Qure.ai Documentation: Security and Privacy FAQ

    Qure.Ai Technologies - Accessed 2026-10-25

    Scope: security

  9. Qure.ai Vulnerability Disclosure Programme

    Qure.ai - Accessed 2026-10-27

    Scope: security, monitoring

Research history

  1. K211222 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K232363

Viz HDS, Viz Volume Plus, Viz ICH+

Viz.ai, Inc.

Authorized purpose: Automatically label, visualize, and quantify segmentable brain structures on single-time-point non-contrast head CT, including intracranial hyperdensities, lateral ventricles, and midline shift; output must be reviewed with the original images by a physician.

Modality
CT/CTA
Anatomy
Brain (intracranial hyperdensities, lateral ventricles, and midline shift)
Decision
2024-02-05
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K243294

Brainomix 360 e-ASPECTS

Brainomix Limited

Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-02-14
FDA-cleared K231570

StrokeViewer Perfusion

NICo-Lab B.V.

Authorized purpose: Provide quantitative perfusion information in brain tissue for suspected ischemic stroke patients using dynamic brain CT perfusion studies; medical imaging professionals use the information as additional data in the standard-of-care assessment, not as a standalone diagnostic tool.

Modality
CT/CTA
Anatomy
Brain
Decision
2023-12-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history